samedan logo
home > pmps > winter 2003 > general considerations for the risk assessment of isolators used for aseptic processes
Pharmaceutical Manufacturing and Packing Sourcer

General Considerations for the Risk Assessment of Isolators used for Aseptic Processes

This article examines the risks associated with the operation of isolators used for aseptic processing activities (aseptic filling and sterility testing) and focuses on risks from microbial and particulate contamination. However some of the preventative measures may be applicable to other forms of contamination.

In exploring the subject of risk assessment, it should be noted that different types of isolators are prone to different contamination risks. Therefore, the risks for isolators used for clinical pharmacy, sterility testing, aseptic filling and so on all differ. The definition of an isolator taken in this article is a device (1):

Provided with microbially retentive filtered air (and which does not exchange any other air with the surrounding environment)
That has a decontamination cycle (for the isolator itself and for material entering)
That has a means for material transfer and/or connection to another isolator
Where no human part directly enters the isolator

All isolators are at risk from contamination. Although isolators are superior in many ways to cleanrooms, the approach of regulators, such as the FDA, is:

"Barrier isolators cannot prevent contamination caused by GMP deficiencies such as poor aseptic procedures and inadequate training of... operators". (2)

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

By Tim Sandle, Microbiologist at Bio Products Laboratory (BPL)

Tim Sandle is the company Microbiologist at Bio Products Laboratory (BPL). BPL is the manufacturing unit of the National Blood Authority, a special health authority within the NHS. Prior to his current role Tim has worked on a number of different microbiological projects within the blood service including developments in the testing of endotoxins and pyrogens for protein-based products; establishing the environmental monitoring regime in the pharmaceutical factory and validating a sterility testing isolator system. Tim has had articles published relating to pharmaceutical microbiology, including LAL testing; operation of isolators; cleanrooms; environmental monitoring and pharmaceutical microbiological testing.

Tim Sandle
Print this page
Send to a friend
Privacy statement
News and Press Releases

First cellularized collagen membrane implant to regenerate heart tissue in patients with ischemic heart disease

• 3P Biopharmaceuticals and Viscofan go ahead with this innovative project of regenerative medicine for cardiac use • Beginning of Phase I clinical trial in a group of 10 patients
More info >>

White Papers

Clinical Trials in Emerging Markets: Goldmines or Landmines?

Pharm-Olam, LLC

Over the past decade, biopharmaceutical companies have increasingly turned to emerging markets as a way to reduce clinical trial costs and timelines. Areas such as Eastern Europe, India, and Latin Americawith their ready population of treatment nave patientscan be an answer to the intense competition for patients seen in developed markets. Many of the countries within these regions may now be considered as emerged countries but yet, conducting trials in these regions does require some special attention and expertise. Before deciding to conduct studies in these areas, companies should have a full appreciation for the ethical, medical, regulatory, legal, and operational hurdles that must be surmounted for success. Here we highlight a number of those issues and offer our recommendations for how sponsor companies can deal with them effectively.
More info >>

Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement